3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Polycystic Ovary Syndrome
10
Insulin Resistance
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Diabetes Mellitus, Type 2
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
2
Carotid Intimal Medial Thickness 1
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
1
Sleep Apnea, Obstructive
1
Skin Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Metabolic Syndrome
1
Meningioma
1
Memory Disorders
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hyperinsulinism
1
Glucose Intolerance
1
Glioblastoma
1
Cognitive Dysfunction
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
358
Cyclophosphamide
241
Azacitidine
213
fludarabine phosphate
199
venetoclax
198
fludarabine
196
Busulfan
148
Decitabine
132
Mycophenolic Acid
123
Whole-Body Irradiation
122
Peripheral Blood Stem Cell Transplantation
118
Tacrolimus
115
Granulocyte Colony-Stimulating Factor
104
Idarubicin
100
Filgrastim
100
Melphalan
89
Cyclosporine
89
Methotrexate
83
Daunorubicin
76
Antilymphocyte Serum
75
Etoposide
73
Mitoxantrone
67
Clofarabine
67
Gemtuzumab
59
Stem Cell Transplantation
55
Thiotepa
51
Cladribine
46
Injections
45
Specimen Handling
44
thymoglobulin
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myeloid, Acute
×
Pioglitazone
×
Clear all
NCT02942758
2024-05-08
AML-ViVA
University Hospital Regensburg
Phase 2
Terminated
10 enrolled